Goldman Sachs has launched coverage of Agilent Technologies, Danaher, and Thermo Fisher Scientific, rating all three as buys with notable price targets indicating substantial upside potential—$170 for Agilent (19%), $265 for Danaher (18%), and $685 for Thermo Fisher (21%). The firm anticipates that the life sciences tools sector will return to a historic market growth rate of about 5%, despite recognizing ongoing softness in early-stage drug discovery. Additionally, Goldman Sachs has rated competitor Bruker as a sell and issued neutral ratings for Revvity and Mettler-Toledo, highlighting a selective view within the sector.
“Goldman Sachs · has initiated coverage of · large-cap life sciences tools companies · Agilent, Danaher, and Thermo Fisher Scientific as buys”
“Goldman Sachs · set a price target for Agilent · Agilent · $170 (~19% upside)”
“Goldman Sachs · set a price target for Danaher · Danaher · $265 (~18% upside)”
“Goldman Sachs · set a price target for Thermo Fisher · Thermo Fisher Scientific · $685 (~21% upside)”
“Goldman Sachs · has launched coverage of · Life Sciences Tools sector · selective stance”
“Goldman Sachs · argues that · Life Sciences Tools group · should return to their historic market growth rate of ~5%”
“Goldman Sachs · has initiated · Thermo Fisher Scientific · Buy rating”
“Goldman Sachs · has initiated · Agilent Technologies · Buy rating”
“Goldman Sachs · has initiated · Danaher · Buy rating”
“Goldman Sachs · started · Thermo Fisher · at Buy with a $685 price target”
“Goldman Sachs · has rated · Agilent · at Buy with a $170 target”
“Goldman Sachs · has rated · Danaher · at Buy with a $265 target”
